Last reviewed · How we verify

Suzhou Kintor Pharmaceutical Inc, — Portfolio Competitive Intelligence Brief

Suzhou Kintor Pharmaceutical Inc, pipeline: 0 marketed, 0 filed, 2 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 4 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Proxalutamide (GT0918) Proxalutamide (GT0918) phase 3 Androgen receptor antagonist Androgen receptor Oncology
KX-826-（5%） BID KX-826-（5%） BID phase 3 Topical androgen receptor antagonist Androgen receptor (AR) Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AEterna Zentaris · 1 shared drug class
  2. CHU de Quebec-Universite Laval · 1 shared drug class
  3. Cassiopea SpA · 1 shared drug class
  4. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  5. Orion Corporation, Orion Pharma · 1 shared drug class
  6. Pfizer · 1 shared drug class
  7. Santa Chiara Hospital · 1 shared drug class
  8. The First Affiliated Hospital with Nanjing Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Suzhou Kintor Pharmaceutical Inc,:

Cite this brief

Drug Landscape (2026). Suzhou Kintor Pharmaceutical Inc, — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/suzhou-kintor-pharmaceutical-inc. Accessed 2026-05-16.

Related